We investigated the validity of quad serum markers for the prediction of adverse pregnancy outcome (APO) in women with antiphospholipid antibody syndrome (APS).
Methods
We included 75 women with APS delivered at our institution. APO was defined as stillbirth, small for gestational age (SGA), severe preeclampsia, or preterm delivery. First, we compared clinical characteristics between patients with or without composite APO. Second, we compared the rate of APO according to abnormal level of quad serum markers. Lastly, receiver operating characteristic (ROC) curve analysis was performed.
Results
APS mothers with APO showed higher median α-fetoprotein (AFP) and inhibin A compared with those without APO. They were also associated with higher rates of positive risk of Down syndrome and neural tube defect. Elevated AFP, human chorionic gonadotropin (hCG), and inhibin A level was associated with higher rates of stillbirth, SGA, preterm delivery, and composite APO. ROC curve for prediction of stillbirth revealed an area under the curve of 0.835 for AFP, 0.781 for hCG, and 0.932 for inhibin A. For composite APO, the area under the ROC curve was 0.692 for AFP and 0.810 for inhibin A.
Conclusion
Elevated AFP, hCG, and inhibin A in women with APS demonstrated a high predictive value for APO, especially stillbirth.
LevineJSBranchDWRauchJ.The antiphospholipid syndrome. N Engl J Med2002;
346: 752–763.
2.
MiyakisSLockshinMDAtsumiT, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006;
4: 295–306.
3.
HögdénAAntovicABergEBremmeKChairetiR.Obstetric outcomes in patients with primary thrombotic and obstetric antiphospholipid syndrome and its relation to the antiphospholipid antibody profile. Lupus2019;
28: 868–877.
4.
OshiroBTSilverRMScottJRYuHBranchDW.Antiphospholipid antibodies and fetal death. Obstet Gynecol1996;
87: 489–493.
5.
Committee on Practice Bulletins-Obstetrics,
American College of Obstetricians Gynecologists. Practice bulletin no. 132: antiphospholipid syndrome. Obstet Gynecol2012;
120: 1514–1521.
YetmanDLKuttehWHCastorenaRBrownCBaskinL.Prevalence of elevated anticardiolipin antibodies in pregnant women with unexplained elevations of alpha-fetoprotein. J Reprod Immunol1997;
33: 71–81.
8.
BrochetCMorinNCoudertMVauthier-BrouzesDCostedoat-ChalumeauNBernardM.Impact of antiphospholipid biology in maternal down syndrome screening. Prenat Diagn2009;
29: 481–488.
9.
DugoffLHobbinsJCMaloneFD, et al.; FASTER Trial Research Consortium.
Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol2005;
106: 260–267.
10.
YaronYCherryMKramerRL, et al.
Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol1999;
181: 968–974.
11.
IlaganJGStamilioDMUralSHMaconesGAOdiboAO.Abnormal multiple marker screens are associated with adverse perinatal outcomes in cases of intrauterine growth restriction. Am J Obstet Gynecol2004;
191: 1465–1469.
12.
GagnonAWilsonRDAudibertF, et al.;
Society of Obstetriciana and Gynaecologists of Canada Genetics Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can2008;
30: 918–932.
13.
Committee on Practice Bulletins-Obstetrics and Committee on Genetics and the Society for Maternal-Fetal Medicine.Practice bulletin no. 163: screening for fetal aneuploidy. Obstet Gynecol2016;
127: e123–137.
14.
PerkinsNJSchistermanEF.The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol2006;
163: 670–675.
SayınNCCandaMTAhmetNArdaSSütNVarolFG.The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns. Arch Gynecol Obstet2007;
277: 47–53.
17.
AnJ-JJiH-YYouJY, et al.
Introduction of a nomogram for predicting adverse pregnancy outcomes based on maternal serum markers in the quad screen test. Arch Gynecol Obstet2015;
292: 589–594.
18.
LaoMRCalhounBCBraceroLA, et al.
The ability of the quadruple test to predict adverse perinatal outcomes in a high-risk obstetric population. J Med Screen2009;
16: 55–59.
19.
DugoffL, Society for Maternal–Fetal Medicine. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol2010;
115: 1052–1061.
20.
GarciaDErkanD.Diagnosis and management of the antiphospholipid syndrome. N Engl J Med2018;
378: 2010–2021.
21.
SammaritanoLR.Antiphospholipid syndrome. Best Pract Res Clin Rheumatol2020;
34: 101463.
22.
AgostinisCBiffiSGarrovoC, et al.
In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions. Blood2011;
118: 4231–4238.
SohMCNelson-PiercyC.Antiphospholipid syndrome in pregnancy. Expert Rev Obstet Gynecol2010;
5: 741–761.
25.
DreuxSSalomonLJMullerF, et al.; ABA Study Group.
Second-trimester maternal serum markers and placenta accreta. Prenat Diagn2012;
32: 1010–1012.
26.
AplinJDBeristainADaSilva-ArnoldS, et al.
IFPA meeting 2016 workshop report III: decidua-trophoblast interactions; trophoblast implantation and invasion; immunology at the maternal-fetal interface; placental inflammation. Placenta2017;
60: S15–S19.
27.
TikkanenMHamalainenENuutilaMPaavonenJYlikorkalaOHiilesmaaV.Elevated maternal second-trimester serum alpha-fetoprotein as a risk factor for placental abruption. Prenat Diagn2007;
27: 240–243.
28.
LyellDJFaucettAMBaerRJ, et al.
Maternal serum markers, characteristics and morbidly adherent placenta in women with previa. J Perinatol2015;
35: 570–574.
29.
BerezowskyAPardoJBen-ZionMWiznitzerAAviramA.Second trimester biochemical markers as possible predictors of pathological placentation: a retrospective case-control study. Fetal Diagn Ther2019;
46: 187–192.
30.
Lambert-MesserlianGMCanickJA.Clinical application of inhibin a measurement: prenatal serum screening for down syndrome. Semin Reprod Med2004;
22: 235–242.
31.
FitzgeraldBLevytskaKKingdomJWalkerMBaczykDKeatingS.Villous trophoblast abnormalities in extremely preterm deliveries with elevated second trimester maternal serum hCG or inhibin-A. Placenta2011;
32: 339–345.
32.
MuttukrishnaS.Role of inhibin in normal and high-risk pregnancy. Semin Reprod Med2004;
22: 227–234.
33.
GalliMBarbuiT.Antiphospholipid antibodies and pregnancy. Best Pract Res Clin Haematol2003;
16: 211–225.
34.
SantosTDSIequeALde CarvalhoHC, et al.
Antiphospholipid syndrome and recurrent miscarriage: a systematic review and meta-analysis. J Reprod Immunol2017;
123: 78–87.
35.
RuffattiATonelloMVisentinMS, et al.
Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology2011;
50: 1684–1689.
36.
SilverRMParkerCBReddyUM, et al.
Antiphospholipid antibodies in stillbirth. Obstet Gynecol2013;
122: 641–657.
37.
SacconeGBerghellaVMaruottiGM, et al.
Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol2017;
216: 525, e1–12.
38.
SilverRMDraperMLByrneJLAshwoodEALyonJLBranchDW.Unexplained elevations of maternal serum alpha-fetoprotein in women with antiphospholipid antibodies: a harbinger of fetal death. Obstet Gynecol1994;
83: 150–155.
39.
PetriMHoACPatelJDemersDJosephJMGoldmanD.Elevation of maternal alpha-fetoprotein in systemic lupus erythematosus: a controlled study. J Rheumatol1995;
22: 1365–1368.
40.
ShamonkiJMSalmonJEHyjekEBaergenRN.Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol2007;
196: 167, e1 61–165.
41.
MaymonRCuckleHSehmiIKHermanAShermanD.Maternal serum human chorionic gonadotrophin levels in systemic lupus erythematosus and antiphospholipid syndrome. Prenat Diagn2001;
21: 143–145.
42.
BartelsHCPostleJDDowneyPBrennanDJ.Placenta accreta spectrum: a review of pathology, molecular biology, and biomarkers. Dis Markers2018;
2018: 1507674.
43.
LakhiNGovindAMorettiMJonesJ.Maternal serum analytes as markers of adverse obstetric outcome. Obstet Gynecol2012;
14: 267–273.
44.
AllyseMMinearMABersonE, et al.
Non-invasive prenatal testing: a review of international implementation and challenges. Int J Womens Health2015;
7: 113–126.
45.
NohJJRyuHMOhSYChoiSJRohCRKimJH.A two-year experience of non-invasive prenatal testing (NIPT) at an urban tertiary medical center in South Korea. Taiwan J Obstet Gynecol2019;
58: 545–551.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
